A low published figure attached to a payment obligation that covers the whole protocol rather than the month.
- Semaglutide$129/mo
- Tirzepatide$149/mo
Assume we may earn a commission, at no cost to you. Partners we work with carry a small, fixed edge in where they are listed; the scores themselves are not adjusted.
- Semaglutide
- $129/mo (billed monthly against a multi-month protocol, compounded)
- Tirzepatide
- $149/mo (billed monthly against a multi-month protocol, compounded)
- Coverage
- Not publicly listed
- Brand-name
- Compounded only
The scorecard
Bayan Health scored on our six published factors. See the methodology.
What we like
- Both molecules are priced under two hundred dollars a month, with the dose ladder stated as one flat price
- Oral drops and a microdose tier are priced below the standard injection, and an oral orforglipron program is priced and purchasable
- The clinical network is named, along with the physician who founded it
- Prices are visible on the product pages before any medical questionnaire
- A transparent-pricing table is published rather than hidden behind an account
The caveats
- The obligation is not monthly: the Terms ship two or three months of medication in one delivery and state that the payment obligation covers the entire protocol dispensed, whatever the billing looks like
- Opting out requires 15 days' notice before the next protocol cycle, which is a longer leash than the cancel-anytime line in the FAQ suggests
- The FAQ says the service is available nationwide while the Terms say it may not be available in all states, and no list exists on the site
- The homepage says medication pricing depends on a personalized plan while the product pages say the price is flat at every dose
- No pharmacy is named, no legal entity suffix or address is published, no phone number exists on the site, and the pricing table still carries an unedited placeholder row
The verdict
Best for: A price-led shopper who will read the auto-renewal clause before the headline convinces them.
Ranked #235 of 548 providers we have reviewed — for comparison, read our CoreAge Rx review, ranked #1. In the ranking it sits between Belle Health at #234, 67/100 above and ARSYNL Rx at #236, 67/100 below, with the BloomWell Rx write-up the next one down.
Bayan Health is one of 548 providers in this ranking, which makes the fair next question who sits above it — our shortlist of Bayan Health alternatives answers it in order, with every score shown. This review sits inside a bigger picture: the complete ranking puts this review in context against every program we track. We have also compared it head to head: CoreAge Rx vs Bayan Health goes to CoreAge Rx, 94/100 to 67/100.
Compare Bayan Health
Compare with other providers
The closest reviews to Bayan Health by Verdict Score — the realistic shortlist if you are weighing this one up.
- #203TelePeptide— TelePeptide is a LegitScript-certified US direct-pay telehealth practice offering physician-supervised compounded GLP-1 therapy — semaglutide and tirzepatide — in injectable and oral dissolvable tablet…69/100
- #204The Aesthetic Concierge— The Aesthetic Concierge is a physician-led US telehealth practice offering GLP-1 medical weight loss.69/100
- #205WePeptideRx— WePeptideRx is a provider-guided telehealth platform offering compounded semaglutide and tirzepatide alongside a deep menu of peptide, hormone, hair, and sexual-wellness programs.69/100
- #206Collective— Medication figures at the low end of everything we rule on, on top of a mandatory annual membership the headline never mentions.66/100
- #207NEUVE Health— A wide catalog and a clean interface around one unanswered question: whether the monthly figure includes the medicine.68/100
- #208The Edit— Introductory compounded care at $200 semaglutide or $300 tirzepatide, followed by higher recurring monthly prices.68/100
Pricing, states and verification reflect Bayan Health's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on Bayan Health's site. Not medical advice; see our disclosure.